期刊文献+

重组人骨形态发生蛋白2缓释微球的制备与评价 被引量:2

Preparation and evaluation of recombinant human bone morphogenetic protein-2 loaded microsphere
在线阅读 下载PDF
导出
摘要 目的:针对重组人骨形态发生蛋白2(recombinant human bone morphogenetic protein-2,rhBMP-2)在体内半衰期短、易被稀释代谢的问题,探讨利用聚乳酸-羟基乙酸共聚物(PLGA)制备载rhBMP-2微球的可行性和制备工艺,并观察其载药、释药特性。方法:①采用W/O/W型复乳化-溶剂挥发技术制备rhBMP-2/PLGA缓释微球,并对微球的粒径和形态、包封率和载药量,体外释放性质进行测定。②异位成骨实验:昆明小鼠12只,在右侧大腿股内侧肌袋内植入含rhBMP-2的50mg PLGA微球,4周后取材,观察成骨情况以初步检测微球中的蛋白质活性。结果:①rhBMP-2/PLGA缓释微球形态良好,粒径主要集中在50~60μm,包封率为(37.52±4.31)%,载药率为(5.12±1.32)%。②微球的释放存在突释,7d内释放的药物量超过40%,大约90%的药物量于42d内释放完全。③载药微球植入鼠股部肌袋4周,材料周围有明显的骨形成。结论:制备的rhBMP-2/PLGA微球可以缓慢释放有活性的rhBMP-2,具有临床应用的可行性。 AIM: Recombinant human bone morphogenetic protein-2 (rhBMP-2) is prone to dilute and conduct metabolism, with a short half-life period in vivo. This study investigated the feasibility and the preparation of rhBMP-2 carrying poly (lactic-co-glycolide) (PLGA), and observed drug-loading and drug-releasing function. METHODS: 1.The rhBMP-2/PLGA microspheres were prepared using W/O/W solvent evaporation method. The particle size and morphology of the microspheres, the drug loading, the efficiency of encapsulation and in vitro release behaviors were detected.2. PLGA microspheres containing 50 mg rhBMP-2 were implanted into medial vastus muscle pouches of right lateral thigh in 12 Kunming mice, and the ectopic bone formation and the activity of rhBMP-2 released from the mierospheres were evaluated 4 weeks later by the heterotopia bone formation experiment.RESULTS: 1.The rhBMP-2/PLGA mierospheres showed good morphology with the particles diameter at 50-60 μm, the envelopment ratio (37.52±4.31 )%, and the ratio of drug loading (5.12±1.32)%.2.Initial burst release of the mierospheres occurred, the drug release exeended 40% within 7 days, and approximately 90% of the drugs was released within 42 days.3.Fonr weeks after the rhBMP-2/PLGA implanted into muscle pouches of mice, obvious bone formation was detectable histologically. CONCLUSION: The rhBMP-2/PLGA mierospheres can release slowly active rhBMP-2, showing a potential clinical application.
出处 《中国组织工程研究与临床康复》 CAS CSCD 北大核心 2008年第6期1001-1004,共4页 Journal of Clinical Rehabilitative Tissue Engineering Research
基金 军队"十一五"基金资助项目(06MA259)~~
  • 相关文献

参考文献20

二级参考文献57

  • 1刘磊,李声伟,田卫东,郑谦,魏世成,熊成东,彭喆.超高分子聚乳酸植入对大鼠的慢性毒性研究[J].四川大学学报(医学版),2004,35(6):764-766. 被引量:1
  • 2张小桥,黎介寿.环孢素A的免疫抑制作用及其机理[J].中国现代普通外科进展,2001,4(3):130-132. 被引量:8
  • 3Jeffery H,Davis SS,O' Hagan DT.Preparation and characterization of poly (lactide-co-glycolide) microspheres Ⅱ:Water-in-oil-in-water emulsion solvent evaporation.Pharm Res,1993,10:362-368.
  • 4Lu L,Stamatas GN,Mikos AG.Controlled release of transforming growth factor b1 from biodegradable polymer microparticles.J Biomed Mater Res,2000,50:440-451.
  • 5Lu JX,About I,Stephan G Histological and biomechanical studies of two bone colonizable cements in rabbits.Bone,1999,25:41-45.
  • 6Yuan H,Li Y,Bruijn JD Tissue responses of calcium phosphate cement:a study in does.Biomaterials,2000,21:1283-1290.
  • 7Simon CG,Khatri CA,Wight SA Preliminary report on the biocompatibility of a moldable,resorbable,composite bone graft consisting of calcium phosphate cement and poly (lactide-co-glycolide) microspheres.J Orthopaedic Res,2002,20:473-482.
  • 8Xu HHK,Janet B.Calcium phosphate cement containing resorbable fibers for short-term reinforcement and macroporosity.Biomaterials,2002,23:193-202.
  • 9Ashammakhi N,Rokkanen P.Absorbable polyglycolide devices in trauma and bone surgery.Biomaterials,1997,18:3-9.
  • 10Xu HHK,Simon CG.Fast setting calcium phosphate-chitosan scaffold:mechanical properties and biocompatibility.Biomaterials,2005,26:1337-1348.

共引文献89

同被引文献50

  • 1段宏,沈彬,王光林,裴福兴.缓释碱性成纤维细胞生长因子微球对膜引导性骨再生的作用[J].中华实验外科杂志,2004,21(12):1526-1528. 被引量:5
  • 2官习鹏,全大萍,廖凯荣,麦堪成.壳聚糖修饰PLGA阳离子型纳米微球的制备与表征[J].高等学校化学学报,2006,27(10):1965-1968. 被引量:9
  • 3Li R, Stewart D J, von Schroeder HP, et al.Effect of cell-based VEGF gene therapy on healing of a segmental bone defect.J Orthop Res. 2009;27(1):8-14.
  • 4Kempen DH, Lu L, Heijink A, et aI.Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration.Biomaterials. 2009;30(14):2816-2825.
  • 5Wang D, Robinson DR, Kwon GS, et aI.Encapsulation of plasmid DNA in biodegradable poly(D, L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery.J Control Release. 1999;57(1 ):9-18.
  • 6Dunne M, Bibby DC, Jones JC, et aI.Encapsulation of protamine sulphate compacted DNA in polylactide and polylactide-co-glycolide microparticles.J Control Release. 2003;92(1-2):209-219.
  • 7Kempen DH, Lu L, Hefferan TE, et aI.Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering.Biomaterials. 2008;29(22):3245-3252.
  • 8Garbayo E, Ansorena E, Lanciego JL, et aI.Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres.Eur J Pharm Biopharm. 2008;69(3):844-851.
  • 9Jin Q, Wei G, Lin Z, et aI.Nanofibrous scaffolds incorporating PDGF-BB microspheres induce chemokine expression and tissue neogenesis in vivo.PLoS One. 2008;3(3): 1729.
  • 10Wenk E, M-einel A J, Wildy S,et alMicroporous silk fibroin scaffolds embedding PLGA microparticles for controlled growth factor delivery in tissue engineering.Biomaterials. 2009; 30(13): 2571-2581.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部